{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:38:56Z","timestamp":1789731536390,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-024-03012-4","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T17:47:58Z","timestamp":1737049678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pediatric Formulation Optimization Using a Rational Design: Exploring Amorphous Solid Dispersion Technology with Terbinafine Hydrochloride as a Case Study"],"prefix":"10.1208","volume":"26","author":[{"given":"Izabelle Amorim Ferreira","family":"Boza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9fani Laise","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolly Bittencourt","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana Carolina","family":"Bazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8499-1627","authenticated-orcid":false,"given":"Hellen Karine","family":"Stulzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"3012_CR1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jaad.2016.08.061","volume":"76","author":"X Chen","year":"2017","unstructured":"Chen X, Jiang X, Yang M, Bennett C, Gonz\u00e1lez U, Lin X, Zhang M. Systemic antifungal therapy for tinea capitis in children: An abridged Cochrane Review. J Am Acad Dermatol. 2017;76:368\u201374.","journal-title":"J Am Acad Dermatol"},{"key":"3012_CR2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejpb.2020.06.012","volume":"153","author":"D Harris","year":"2020","unstructured":"Harris D, Hermans E, Klein S, Wagner-Hattler L, Walsh J. Age-appropriate solid oral formulations for pediatric applications with a focus on multiparticulates and minitablets. Eur J Pharm Biopharm. 2020;153:222\u20135.","journal-title":"Eur J Pharm Biopharm"},{"key":"3012_CR3","doi-asserted-by":"crossref","first-page":"114084","DOI":"10.1016\/j.addr.2021.114084","volume":"181","author":"E Wollmer","year":"2022","unstructured":"Wollmer E, Ungell AL, Nicolas JM, Klein S. Review of paediatric gastrointestinal physiology relevant to the absorption of orally administered medicines. Adv Drug Deliv Rev. 2022;181:114084.","journal-title":"Adv Drug Deliv Rev"},{"key":"3012_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejpb.2020.08.014","volume":"156","author":"L Freerks","year":"2020","unstructured":"Freerks L, Sommerfeldt J, L\u00f6per PC, Klein S. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications. Eur J Pharm Biopharm. 2020;156:11\u20139.","journal-title":"Eur J Pharm Biopharm"},{"key":"3012_CR5","doi-asserted-by":"crossref","first-page":"105437","DOI":"10.1016\/j.ejps.2020.105437","volume":"152","author":"V Bhatt-Mehta","year":"2020","unstructured":"Bhatt-Mehta V, Hammoud H, Amidon GL. A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children. Eur J Pharm Sci. 2020;152:105437.","journal-title":"Eur J Pharm Sci"},{"key":"3012_CR6","doi-asserted-by":"crossref","first-page":"119905","DOI":"10.1016\/j.ijpharm.2020.119905","volume":"590","author":"M Moreira","year":"2020","unstructured":"Moreira M, Sarragu\u00e7a M. How can oral paediatric formulations be improved? A challenge for the XXI century. Int J Pharm. 2020;590:119905.","journal-title":"Int J Pharm"},{"issue":"4","key":"3012_CR7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.xphs.2018.11.013","volume":"108","author":"RG Strickley","year":"2019","unstructured":"Strickley RG. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007. J Pharm Sci. 2019;108(4):1335\u201365.","journal-title":"J Pharm Sci"},{"key":"3012_CR8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/ph15010108","volume":"15","author":"G Zuccari","year":"2022","unstructured":"Zuccari G, Alfei S, Marimpietri D, Iurilli V, Barabino P, Marchitto L. Mini-tablets: A valid strategy to combine efficacy and safety in pediatrics. Pharmaceuticals. 2022;15:108.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"3012_CR9","first-page":"78","volume":"60","author":"BA Kondoros","year":"2020","unstructured":"Kondoros BA, Laczkovich O, Berkesi O, Aigner Z. Analytical investigation of cyclodextrin complexation using the co-grinding technique in the case of terbinafine hydrochloride. Proceedings. 2020;60(1):78.","journal-title":"Proceedings"},{"issue":"1","key":"3012_CR10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1208\/s12248-008-9023-x","volume":"10","author":"M Tubic-Grozdanis","year":"2008","unstructured":"Tubic-Grozdanis M, Bolger MB, Langguth P. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J. 2008;10(1):213\u201326.","journal-title":"AAPS J"},{"key":"3012_CR11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.addr.2016.02.001","volume":"101","author":"SD Kr\u00e4mer","year":"2016","unstructured":"Kr\u00e4mer SD, Aschmann HE, Hatibovic M, Hermann KF, Neuhaus CS, Brunner C, Belli S. When barriers ignore the \u201crule-of-five.\u201d Adv Drug Deliv Rev. 2016;101:62\u201374.","journal-title":"Adv Drug Deliv Rev"},{"key":"3012_CR12","doi-asserted-by":"crossref","first-page":"121498","DOI":"10.1016\/j.ijpharm.2022.121498","volume":"615","author":"MT Fran\u00e7a","year":"2022","unstructured":"Fran\u00e7a MT, Marcos TM, Costa PF, Bazzo GC, Pereira RN, Gerola AP, Stulzer HK. Eutectic mixture and amorphous solid dispersion: Two different supersaturating drug delivery system strategies to improve griseofulvin release using saccharin. Int J Pharm. 2022;615:121498.","journal-title":"Int J Pharm"},{"issue":"8","key":"3012_CR13","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.apsb.2021.05.014","volume":"11","author":"SV Bhujbal","year":"2021","unstructured":"Bhujbal SV, Mitra B, Jain U, Gong Y, Agrawal A, Karki S, Taylor LS, Kumar S, Zhou QT. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharm Sin B. 2021;11(8):2505\u201336.","journal-title":"Acta Pharm Sin B."},{"key":"3012_CR14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijpharm.2017.10.051","volume":"535","author":"SV Jermain","year":"2018","unstructured":"Jermain SV, Brough C, Williams RO. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery: an update. Int J Pharm. 2018;535:379\u201392.","journal-title":"Int J Pharm"},{"issue":"1","key":"3012_CR15","first-page":"9","volume":"3","author":"S Debnath","year":"2013","unstructured":"Debnath S, Kumar GV, Satyanarayana SV. Preparation and evaluation of solid dispersion of terbinafine hydrochloride. Asian J Pharm Technol. 2013;3(1):9\u201315.","journal-title":"Asian J Pharm Technol"},{"issue":"4","key":"3012_CR16","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/pharmaceutics14040744","volume":"14","author":"BA Kondoros","year":"2022","unstructured":"Kondoros BA, J\u00f3j\u00e1rt-Laczkovich O, Berkesi O, Szab\u00f3-R\u00e9v\u00e9sz P, Cs\u00f3ka I, Ambrus R, Aigner Z. Development of solvent-free co-ground method to produce terbinafine hydrochloride cyclodextrin binary systems; structural and in vitro characterizations. Pharmaceutics. 2022;14(4):744.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3012_CR17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/0973-8398.43301","volume":"2","author":"N Kumar","year":"2008","unstructured":"Kumar N, Jain AK, Singh C, Kumar R. Development, characterization and solubility study of solid dispersion of terbinafine hydrochloride by solvent evaporation method. Asian J Pharm (AJP). 2008;2(3):154.","journal-title":"Asian J Pharm (AJP)"},{"key":"3012_CR18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2015.05.018","volume":"77","author":"FA Meng","year":"2015","unstructured":"Meng FA, Vivek DB, Chauhan H. Qualitative and quantitative methods to determine miscibility in amorphous drug\u2013polymer systems. Eur J Pharm Sci. 2015;77:106\u201311.","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"3012_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/pen.760140211","volume":"14","author":"RF Fedors","year":"1974","unstructured":"Fedors RF. A method for estimating both the solubility parameters and molar volumes of liquids. Polym Eng Sci. 1974;14(2):147\u201354.","journal-title":"Polym Eng Sci"},{"issue":"1","key":"3012_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(96)04828-4","volume":"148","author":"BC Hancock","year":"1997","unstructured":"Hancock BC, York P, Rowe RC. The use of solubility parameters in pharmaceutical dosage form design. Int J Pharm. 1997;148(1):1\u201321.","journal-title":"Int J Pharm"},{"key":"3012_CR21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpb.2016.02.009","volume":"102","author":"B Hossin","year":"2016","unstructured":"Hossin B, Rizi K, Murdan S. Application of Hansen Solubility Parameters to predict drug\u2013nail interactions, which can assist the design of nail medicines. Eur J Pharm Biopharm. 2016;102:32\u201340.","journal-title":"Eur J Pharm Biopharm"},{"key":"3012_CR22","doi-asserted-by":"crossref","unstructured":"Sambhakar S, Thimmasetty J, Nayak S, Pravin SJ. Introduction of new method for prediction of solubility parameter using aripiprazole as a model drug. Chem Data Collect. 2023;44.","DOI":"10.1016\/j.cdc.2023.100995"},{"key":"3012_CR23","doi-asserted-by":"crossref","unstructured":"Parra MA, Cerquera NE, Ortiz CP, C\u00e1rdenas-Torres RE, Delgado DR, Pe\u00f1a M\u00c1, Mart\u00ednez F. Solubility of ciprofloxacin in different solvents at several temperatures: Measurement, correlation, thermodynamics and Hansen solubility parameters. J Taiwan Inst Chem Eng. 2023;150.","DOI":"10.1016\/j.jtice.2023.105028"},{"key":"3012_CR24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/pharmaceutics14020330","volume":"14","author":"M Zhang","year":"2022","unstructured":"Zhang M, Wu B, Zhang S, Wang L, Hu Q, Liu D, Chen X. Characterizing the physicochemical properties of two weakly basic drugs and the precipitates obtained from biorelevant media. Pharmaceutics. 2022;14:330.","journal-title":"Pharmaceutics"},{"key":"3012_CR25","doi-asserted-by":"crossref","first-page":"106752","DOI":"10.1016\/j.ejps.2024.106752","volume":"196","author":"AA Virtanen","year":"2024","unstructured":"Virtanen AA, My\u015bli\u0144ska M, Healy AM, Power E, Madi A, Siv\u00e9n M. The challenge of downstream processing of spray dried amorphous solid dispersions into minitablets designed for the paediatric population\u2013A sustainable product development approach. Eur J Pharm Sci. 2024;196:106752.","journal-title":"Eur J Pharm Sci"},{"key":"3012_CR26","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1021\/acs.jmedchem.1c01687","volume":"65","author":"WP Wuelfing","year":"2022","unstructured":"Wuelfing WP, Marrouni AE, Lipert MP, Daublain P, Kesisoglou F, Converso A, Templeton AC. Dose number as a tool to guide lead optimization for orally bioavailable compounds in drug discovery. J Med Chem. 2022;65:1685\u201394.","journal-title":"J Med Chem"},{"issue":"5","key":"3012_CR27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1208\/s12249-021-02069-9","volume":"22","author":"A Butreddy","year":"2022","unstructured":"Butreddy A, Sarabu S, Bandari S, Batra A, Lawal K, Chen NN, Bi V, Durig V, Repka MA. Influence of Plasdone\u2122 S630 Ultra\u2014an improved copovidone on the processability and oxidative degradation of quetiapine fumarate amorphous solid dispersions prepared via hot-melt extrusion technique. AAPS Pharm Sci Tech. 2022;22(5):196.","journal-title":"AAPS Pharm Sci Tech"},{"issue":"2","key":"3012_CR28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2006.08.010","volume":"328","author":"AN Ghebremeskel","year":"2007","unstructured":"Ghebremeskel AN, Vemavarapu C, Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer\u2013surfactant combinations using solubility parameters and testing the processability. Int J Pharm. 2007;328(2):119\u201329.","journal-title":"Int J Pharm"},{"key":"3012_CR29","doi-asserted-by":"crossref","unstructured":"Batchelor H (on behalf of European Paediatric Formulation Initiative (EuPFI). Paediatric biopharmaceutics classification system: Current status and future decisions. Int J Pharmaceutics 2014;469:251-253.","DOI":"10.1016\/j.ijpharm.2014.02.046"},{"key":"3012_CR30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1208\/s12248-016-9885-2","volume":"18","author":"S Ramzi","year":"2016","unstructured":"Ramzi S. Pediatric biopharmaceutical classification system: using age-appropriate initial gastric volume. AAPS J. 2016;18:728\u201336.","journal-title":"AAPS J"},{"key":"3012_CR31","volume-title":"Developing solid oral dosage forms","author":"Y Qiu","year":"2017","unstructured":"Qiu Y, Chen Y, Zhang GG, Yu I, Mantri R. Developing solid oral dosage forms. Academic Press; 2017."},{"key":"3012_CR32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/pharmaceutics14030473","volume":"14","author":"J Walsh","year":"2022","unstructured":"Walsh J, Masini T, Huttner B, Moja L, Penazzato M, Cappello B. Assessing the appropriateness of formulations on the who model list of essential medicines for children: Development of a paediatric quality target product profile tool. Pharmaceutics. 2022;14:473.","journal-title":"Pharmaceutics"},{"key":"3012_CR33","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/jcph.1138","volume":"58","author":"Y Thabet","year":"2018","unstructured":"Thabet Y, Klingmann V, Breitkreutz J. Drug formulations: Standards and novel strategies for drug administration in pediatrics. J Clin Pharm. 2018;58:S26\u201335.","journal-title":"J Clin Pharm"},{"issue":"3","key":"3012_CR34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"HK Batchelor","year":"2015","unstructured":"Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Brit J Clin Pharmacol. 2015;79(3):395\u2013404.","journal-title":"Brit J Clin Pharmacol"},{"key":"3012_CR35","first-page":"30","volume":"9","author":"G Schmitt","year":"2022","unstructured":"Schmitt G. Safety of Soluplus\u00ae in Pediatrics. Appl Drug Res Clin Trials Regul Aff. 2022;9:30\u20132.","journal-title":"Appl Drug Res Clin Trials Regul Aff"},{"issue":"3","key":"3012_CR36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10837451003774377","volume":"16","author":"SB Murdande","year":"2011","unstructured":"Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement. Pharm Dev Technol. 2011;16(3):187\u2013200.","journal-title":"Pharm Dev Technol"},{"key":"3012_CR37","unstructured":"FOOD AND DRUG ADMINISTRATION (FDA) regulatory information: Guidance for Industry Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients.Available at: <https:\/\/www.fda.gov\/media\/72260\/download>. Accessed Sept 2024."},{"key":"3012_CR38","unstructured":"Soluplus\u00ae For better solubility and bioavailability.Available at: <https:\/\/www.pharmaexcipients.com\/wp-content\/uploads\/attachments\/BASF_Soluplus_Onepager.pdf?t=1532108514> Accessed Sept 2024."},{"key":"3012_CR39","unstructured":"PHARMACOMPASS. Available at: <https:\/\/www.pharmacompass.com\/us-drug-master-files-dmfs\/plasdone-s630> Accessed Sept 2024."},{"key":"3012_CR40","unstructured":"BioSPace. Available at: <https:\/\/www.biospace.com\/bend-research-clients-may-now-reference-key-safety-document-for-important-solubility-excipient> Accessed Sept 2024."},{"key":"3012_CR41","doi-asserted-by":"crossref","first-page":"106098","DOI":"10.1016\/j.ejps.2021.106098","volume":"170","author":"JP O'Shea","year":"2022","unstructured":"O\u2019Shea JP, Augustijns P, Brandl M, Brayden DJ, Brouwers J, Griffin BT, Holm R, Jacobsen AC, Lennern\u00e4s H, Vinarov Z, O\u2019Driscoll CM. Best practices in current models mimicking drug permeability in the gastrointestinal tract-An UNGAP review. Eur J Pharm Sci. 2022;170:106098.","journal-title":"Eur J Pharm Sci"},{"key":"3012_CR42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10847-009-9656-0","volume":"66","author":"M Uzqueda","year":"2010","unstructured":"Uzqueda M, et al. Physicochemical characterization of terbinafine-cyclodextrin complexes in solution and in the solid state. J Incl Phenom Macrocycl Chem. 2010;66:393\u2013402.","journal-title":"J Incl Phenom Macrocycl Chem"},{"issue":"2","key":"3012_CR43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejps.2013.03.013","volume":"49","author":"H Vaghasiya","year":"2013","unstructured":"Vaghasiya H, Kumar A, Sawant K. Development of terbinafine solid lipid nanoparticles as a topical delivery system. Eur J Pharm Sci. 2013;49(2):311\u201322.","journal-title":"Eur J Pharm Sci"},{"key":"3012_CR44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejps.2016.04.004","volume":"88","author":"SM AbdelSamie","year":"2016","unstructured":"AbdelSamie SM, Kamel AO, Sammour OA, Ibrahim SM. Terbinafine hydrochloride nanovesicular gel: In vitro characterization, ex vivo permeation and clinical investigation. Eur J Pharm Sci. 2016;88:91\u2013100.","journal-title":"Eur J Pharm Sci"},{"key":"3012_CR45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.carbpol.2017.12.052","volume":"184","author":"JMO Pinto","year":"2018","unstructured":"Pinto JMO, Le\u00e3o AM, Riekes MK, Fran\u00e7a MT, Stulzer HK. HPMCAS as an effective precipitation inhibitor in amorphous solid T dispersions of the poorly soluble drug candesartan cilexetil. Carbohyd Polym. 2018;184:199\u2013206.","journal-title":"Carbohyd Polym"},{"key":"3012_CR46","first-page":"117","volume":"4","author":"T Higuchi","year":"1965","unstructured":"Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instr. 1965;4:117\u2013212.","journal-title":"Adv Anal Chem Instr"},{"key":"3012_CR47","doi-asserted-by":"crossref","first-page":"105138","DOI":"10.1016\/j.ejps.2019.105138","volume":"142","author":"L Klumpp","year":"2020","unstructured":"Klumpp L, Leigh M, Dressman J. Dissolution behavior of various drugs in different FaSSIF versions. Eur J Pharm Sci. 2020;142:105138.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"3012_CR48","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","volume":"105","author":"S Baghel","year":"2016","unstructured":"Baghel S, Cathcart H, O\u2019Reilly NJ. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 2016;105(9):2527\u201344.","journal-title":"J Pharm Sci"},{"key":"3012_CR49","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.55522\/jmpas.V12I1.4067","volume":"12","author":"R Seenivasan","year":"2023","unstructured":"Seenivasan R, Iyer SS, Narayanasamy VP, Krishnan V, Anand MI, Venkatesh DN. Solubility enhancement of terbinafine hydrochloride by hydrotropic technique. J Med Pharm Allied Sci. 2023;12:5596\u2013603.","journal-title":"J Med Pharm Allied Sci"},{"key":"3012_CR50","doi-asserted-by":"crossref","first-page":"108455","DOI":"10.1016\/j.exppara.2022.108455","volume":"248","author":"S Paulino","year":"2023","unstructured":"Paulino S, Santos L, Rabello M, da Silva P, Oliveira J, van Carmo Lima M, Rocha T, Albuquerque M, Santos V, Alves L, Brayner F. Development of solid dispersions based on 3-(2, 6-difluorobenzyl)-5-(5-bromo-1H-indol-3-ylmethylene) thiazolidine-2, 4-dione for schistosomicidal treatment. Exp Parasitol. 2023;248:108455.","journal-title":"Exp Parasitol"},{"key":"3012_CR51","doi-asserted-by":"crossref","first-page":"115828","DOI":"10.1016\/j.carbpol.2020.115828","volume":"233","author":"S Sarabu","year":"2020","unstructured":"Sarabu S, Kallakunta VR, Bandari S, Batra A, Bi V, Durig T, Zhang F, Repka MA. Hypromellose acetate succinate based amorphous solid dispersions via hot melt extrusion: effect of drug physicochemical properties. Carbohydr Polym. 2020;233:115828.","journal-title":"Carbohydr Polym"},{"key":"3012_CR52","unstructured":"Waisczik CHR. Desenvolvimento de membranas bioadesivas de kcarragenana e hidroxipropilmetilcelulose acetato succinato visando a administra\u00e7\u00e3o t\u00f3pica de cloridrato de terbinafina. 2020. Disserta\u00e7\u00e3o (Programa de P\u00f3s Gradua\u00e7\u00e3o em Qu\u00edmica) - Universidade Federal de Santa Catarina, Florian\u00f3polis, 2020."},{"key":"3012_CR53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpba.2013.02.001","volume":"78","author":"G Kuminek","year":"2013","unstructured":"Kuminek G, et al. Single crystal structure, solid state characterization and dissolution rate of terbinafine hydrochloride. J Pharm Biomed Anal. 2013;78:105\u201311.","journal-title":"J Pharm Biomed Anal"},{"key":"3012_CR54","doi-asserted-by":"crossref","first-page":"102280","DOI":"10.1016\/j.jddst.2020.102280","volume":"61","author":"A Hajare","year":"2021","unstructured":"Hajare A, Dol H, Patil K. Design and Development of Terbinafine Hydrochloride Ethosomal Gel for Enhancement of Transdermal Delivery: In Vitro, In Vivo, Molecular Docking, and Stability Study. J Drug Deliv Sci Technol. 2021;61:102280.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3012_CR55","doi-asserted-by":"crossref","first-page":"102935","DOI":"10.1016\/j.jddst.2021.102935","volume":"66","author":"F Pervaiz","year":"2021","unstructured":"Pervaiz F, Mushtaq R, Noreen S. Formulation and optimization of terbinafine HCl loaded chitosan\/xanthan gum nanoparticles containing gel: Ex-vivo permeation and in-vivo antifungal studies. J Drug Deliv Sci Technol. 2021;66:102935.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3012_CR56","doi-asserted-by":"crossref","first-page":"110673","DOI":"10.1016\/j.colsurfb.2019.110673","volume":"187","author":"JMO Pinto","year":"2020","unstructured":"Pinto JMO, Rengifo AFC, Mendes C, Le\u00e3o AF, Parize AL, Stulzer HK. Understanding the interaction between Soluplus\u00ae and biorelevant media components. Colloids Surf B: Biointerfaces. 2020;187:110673.","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"3012_CR57","first-page":"85","volume":"11","author":"T Higuchi","year":"1960","unstructured":"Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem. 1960;11:85\u201397.","journal-title":"J Soc Cosmet Chem"},{"key":"3012_CR58","first-page":"2189","volume":"6","author":"H Guzm\u00e1n","year":"2004","unstructured":"Guzm\u00e1n H. A\" spring and parachute\" approach to design solid celecoxib formulations having enhanced oral absorption. AAPS J. 2004;6:2189.","journal-title":"AAPS J"},{"key":"3012_CR59","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/jps.20906","volume":"96","author":"H Guzm\u00e1n","year":"2007","unstructured":"Guzm\u00e1n H, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Mustonen P, Gardner C, Chen H, Moreau J, Almarsson O, Remenar J. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96:2686\u2013702.","journal-title":"J Pharm Sci"},{"key":"3012_CR60","doi-asserted-by":"crossref","first-page":"122524","DOI":"10.1016\/j.ijpharm.2022.122524","volume":"631","author":"Y Kong","year":"2023","unstructured":"Kong Y, Wang W, Wang C, Li L, Peng D, Tian B. Supersaturation and phase behavior during dissolution of amorphous solid dispersions. Int J Pharm. 2023;631:122524.","journal-title":"Int J Pharm"},{"key":"3012_CR61","first-page":"9","volume":"2","author":"KP Kashinath","year":"2024","unstructured":"Kashinath KP, Sardar MS, Sah SK, Kaity S. Chapter 2 - Stability and accelerated stability studies of dosage forms. Physico-Chem Asp Dosage Forms Biopharm. 2024;2:9\u201342.","journal-title":"Physico-Chem Asp Dosage Forms Biopharm"},{"key":"3012_CR62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.powtec.2012.12.038","volume":"237","author":"RN Shamma","year":"2013","unstructured":"Shamma RN, Basha M. Soluplus\u00ae: A novel polymeric solubilizer for optimization of Carvedilol solid dispersions: Formulation design and effect of method of preparation. Powder Technol. 2013;237:406\u201314.","journal-title":"Powder Technol"},{"key":"3012_CR63","doi-asserted-by":"crossref","first-page":"116228","DOI":"10.1016\/j.trac.2021.116228","volume":"138","author":"A Kaur","year":"2021","unstructured":"Kaur A, Kale DP, Bansal AK. Surface characterization of Pharmaceutical solids. Trends Anal Chem. 2021;138:116228.","journal-title":"Trends Anal Chem"},{"key":"3012_CR64","doi-asserted-by":"crossref","first-page":"e22452","DOI":"10.1590\/s2175-97902023e22452","volume":"59","author":"H Hajhashemi","year":"2023","unstructured":"Hajhashemi H, Taymouri S, Shafiee F. Development and evaluation of wafer loaded with sertaconazole solid dispersion for the treatment of oral candidiasis. Braz J Pharm Sci. 2023;59:e22452.","journal-title":"Braz J Pharm Sci"},{"key":"3012_CR65","doi-asserted-by":"crossref","first-page":"120505","DOI":"10.1016\/j.ijpharm.2021.120505","volume":"600","author":"NK Thakral","year":"2021","unstructured":"Thakral NK, Meister E, Jankovsky C, Li L, Schwabe R, Luo L, Chen S. Prediction of in vivo supersaturation and precipitation of poorly water-soluble drugs: Achievements and aspirations. Int J Pharm. 2021;600:120505.","journal-title":"Int J Pharm"},{"key":"3012_CR66","first-page":"100834","volume":"18","author":"J Zhang","year":"2023","unstructured":"Zhang J, Guo M, Luo M, Cai T. Advances in the development of amorphous solid dispersions: The role of polymeric carriers. Asian J Pharm Sci. 2023;18:100834.","journal-title":"Asian J Pharm Sci"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-03012-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-024-03012-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-03012-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:28:07Z","timestamp":1739975287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-024-03012-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3012"],"URL":"https:\/\/doi.org\/10.1208\/s12249-024-03012-4","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}],"article-number":"40"}}